1. Usage of compromised lung volume in monitoring steroid therapy on severe COVID-19
- Author
-
Ying Su, Ze-song Qiu, Jun Chen, Min-jie Ju, Guo-guang Ma, Jin-wei He, Shen-ji Yu, Kai Liu, Fleming Y. M. Lure, Guo-wei Tu, Yu-yao Zhang, and Zhe Luo
- Subjects
Steroid ,Quantitative computed tomography ,Compromised lung volume ,COVID-19 ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Quantitative computed tomography (QCT) analysis may serve as a tool for assessing the severity of coronavirus disease 2019 (COVID-19) and for monitoring its progress. The present study aimed to assess the association between steroid therapy and quantitative CT parameters in a longitudinal cohort with COVID-19. Methods Between February 7 and February 17, 2020, 72 patients with severe COVID-19 were retrospectively enrolled. All 300 chest CT scans from these patients were collected and classified into five stages according to the interval between hospital admission and follow-up CT scans: Stage 1 (at admission); Stage 2 (3–7 days); Stage 3 (8–14 days); Stage 4 (15–21 days); and Stage 5 (22–31 days). QCT was performed using a threshold-based quantitative analysis to segment the lung according to different Hounsfield unit (HU) intervals. The primary outcomes were changes in percentage of compromised lung volume (%CL, − 500 to 100 HU) at different stages. Multivariate Generalized Estimating Equations were performed after adjusting for potential confounders. Results Of 72 patients, 31 patients (43.1%) received steroid therapy. Steroid therapy was associated with a decrease in %CL (− 3.27% [95% CI, − 5.86 to − 0.68, P = 0.01]) after adjusting for duration and baseline %CL. Associations between steroid therapy and changes in %CL varied between different stages or baseline %CL (all interactions, P
- Published
- 2022
- Full Text
- View/download PDF